Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 24, 2012

FDA Clears Subcutaneous Velcade for All Approved Indications

  • FDA cleared the subcutaneous administration of Takeda’s Velcade (bortezomib) for all approved indications, which currently including multiple myeloma and mantle cell lymphoma.

    The agency’s sNDA approval was based on positive data from a Phase III noninferiority study in 222 bortezomib-naive patients with relapsed multiple myeloma, which was designed to demonstrate that single agent subcutaneous Velcade retained at least 60% of the overall response rate after four cycles, relative to single agent intravenous Velcade.

    Velcade is approved in over 90 countries worldwide. The drug has been codeveloped by Takeda’s Millennium, and Janssen Pharmaceutical. Millennium commercializes Velcade in the U.S., and Janssen’s responsibility covers Europe and the rest of the world. Takeda and Janssen’s Japanese businesses co-promote Velcade in Japan. 



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »